Evidence map›Paper›PMID 26678998›Full record

ArticlePloS one2015

Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression.

Robert M Paris, Constantinos Petrovas, Sara Ferrando-Martinez, Eirini Moysi, Kristin L Boswell, Eva Archer, Takuya Yamamoto, David Ambrozak, Joseph P Casazza, Richard Haubrich and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Article
  5. Bone Marrow-Derived CD4Journal of virology · 2019
    Article
  6. PD-1 Expression onFrontiers in immunology · 2018
    Article
  7. Article
  8. CTLA-4Immunity · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Robert M ParisImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Constantinos PetrovasImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Sara Ferrando-MartinezImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Eirini MoysiImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Kristin L BoswellImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Eva ArcherImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Takuya YamamotoImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
David AmbrozakImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Joseph P CasazzaImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
Richard HaubrichDivision of Infectious Diseases, Antiviral Research Center, University of California San Diego, San Diego, California, United States of America.
Mark ConnorsHIV-Specific Immunity Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, United States of America.
Julie AkeUnited States Military HIV Research Program, Silver Spring, Maryland, United States of America.
Jerome H KimInternational Vaccine Institute, Seoul, South Korea.
Richard A KoupImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America.
National Institutes of Health · USInternational Vaccine Institute · KRNational Institute of Allergy and Infectious Diseases · USUniversity of California, San Diego · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNPZIAAI000855 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$20.0M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
Mechanisms of Effective Humoral Immune Responses to HIV-1ZIAAI001090 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$14.8M
Improving Antiretroviral Management for HIVK24AI064086 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAUBRICH, RICHARD H · 2006 to 2015
$1.8M
FILARIASIS REPOSITORY RESEARCH SERVICEN01AI002642 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI MC CALL, JOHN W · 1985 to 1987
–
Intramural NIH HHSNIAID NIH HHS AI064086NIAID NIH HHS AI36214NIAID NIH HHS AI69432NIAID NIH HHS K24 AI064086NIAID NIH HHS P30 AI036214NIAID NIH HHS U01 AI069432NIAID NIH HHS UM1 AI069432NIAID NIH HHS Y1-AI-2642-12
6 · The paper itself

Abstract

The role of PD-1 expression on CD4 T cells during HIV infection is not well understood. Here, we describe the differential expression of PD-1 in CD127high CD4 T cells within the early/intermediate differentiated (EI) (CD27highCD45RAlow) T cell population among uninfected and HIV-infected subjects, with higher expression associated with decreased viral replication (HIV-1 viral load). A significant loss of circulating PD-1highCTLA-4low CD4 T cells was found specifically in the CD127highCD27highCD45RAlow compartment, while initiation of antiretroviral treatment, particularly in subjects with advanced disease, reversed these dynamics. Increased HIV-1 Gag DNA was also found in PD-1high compared to PD-1low ED CD4 T cells. In line with an increased susceptibility to HIV infection, PD-1 expression in this CD4 T cell subset was associated with increased activation and expression of the HIV co-receptor, CCR5. Rather than exhaustion, this population produced more IFN-g, MIP1-a, IL-4, IL-10, and IL-17a compared to PD-1low EI CD4 T cells. In line with our previous findings, PD-1high EI CD4 T cells were also characterized by a high expression of CCR7, CXCR5 and CCR6, a phenotype associated with increased in vitro B cell help. Our data show that expression of PD-1 on early-differentiated CD4 T cells may represent a population that is highly functional, more susceptible to HIV infection and selectively lost in chronic HIV infection.

Indexed as

Anti-HIV AgentsCD4 Lymphocyte CountCD4-Positive T-LymphocytesCytokinesDisease ProgressionFlow CytometryHIV-1HIV InfectionsHumansPolymerase Chain ReactionProgrammed Cell Death 1 ReceptorReceptors, CCR5Viral LoadAnti-HIV AgentsCCR5 protein, humanCytokinesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CCR5

Identifiers

PMID26678998
PMCPMC4692060
OpenAlexW2275493451

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.